ADAP News and Press, Adaptimmune Therapeutics plc From 01/14/20

RTI Surgical Holdings (NASDAQ: RTIX ) +105%  on sale of OEM business . More news on: RTI Surgical Holdings, Inc., TransEnterix, Inc., XBiotech Inc., Stocks on the move, , Read more ...

January 14, 2020 Palm Beach, FL –January 14, 2020 – Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of t...

Adaptimmune Therapeutics (NASDAQ: ADAP ) inks an agreement with Astellas Pharma ( OTCPK:ALPMF ) aimed at co-developing and co-commercializing up to three T-cell therapies in cancer. More news on: Adaptimmune Therapeutics plc, Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks ...

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform - - Astellas will pay Adaptimmune an upfront payme...

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...

Are These On Your Penny Stocks Watch List This Week? Over the years, thousands of investors have been able to make fortunes through clever investments in penny stocks . Hence, it is no surprise that these stocks are almost always in high demand. However, it is also true that investors need to...

Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56%  as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective i...

Adaptimmune Therapeutics (NASDAQ: ADAP ) is up  60%  premarket after reporting  two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks o...

- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2...